Recently mathematical modeling of EGFR inhibition in metastatic colon cancer suggests that the likely number of preexisting resistance mutations make it virtually impossible for a single targeting agent to prevent tumor re-growth [22]. This evidence concerns the gene EGFR and neoplasm.